Long term effectiveness of COBRA-light and COBRA treatment in early rheumatoid arthritis

Long term effectiveness of COBRA-light and COBRA treatment in early rheumatoid arthritis - COBRA-light four year extension study

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON39638

Enrollment

162

Registered

2012-12-11

Start date

2013-04-04

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: All patients who participated in the COBRA-light-study (and who started with the therapy).

Exclusion criteria

Exclusion criteria: Patients who did not start with the COBRA therapy

Design outcomes

Primary

Measure	Time frame
The most important parameters of the follow-up study are the status of disease activity (DAS44 score), functional capacity (HAQ score) and radiological progression (Sharp/van der Heijde score) per treatment group after 48 months. The results of both treatment groups will be compared with each other. In addition, the average disease activity, functional capacity and radiological progression of the past 48 months will be calculated and compared between treatment both groups.	—

Measure

Time frame

The most important parameters of the follow-up study are the status of disease activity (DAS44 score), functional capacity (HAQ score) and radiological progression (Sharp/van der Heijde score) per treatment group after 48 months. The results of both treatment groups will be compared with each other. In addition, the average disease activity, functional capacity and radiological progression of the past 48 months will be calculated and compared between treatment both groups.

—

Secondary

Measure	Time frame
Secondary study parameters of the study are the level of improvement of the patients (ACR response score), RA medication use, adverse events and potential additional medication use and the Charlson Comorbidity Index (CCI).	—

Countries

Netherlands

Outcome results